Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Cash & Equivalents (2022 - 2025)

Historic Cash & Equivalents for PAVmed (PAVM) over the last 4 years, with Q3 2025 value amounting to $31.6 million.

  • PAVmed's Cash & Equivalents changed N/A to $31.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.6 million, marking a year-over-year change of. This contributed to the annual value of $25.6 million for FY2024, which is 3054.13% up from last year.
  • According to the latest figures from Q3 2025, PAVmed's Cash & Equivalents is $31.6 million.
  • PAVmed's 5-year Cash & Equivalents high stood at $65.2 million for Q2 2022, and its period low was $16.5 million during Q3 2024.
  • Over the past 4 years, PAVmed's median Cash & Equivalents value was $36.0 million (recorded in 2025), while the average stood at $37.8 million.
  • Per our database at Business Quant, PAVmed's Cash & Equivalents tumbled by 5349.48% in 2023 and then surged by 8264.8% in 2025.
  • Quarter analysis of 4 years shows PAVmed's Cash & Equivalents stood at $39.7 million in 2022, then crashed by 50.59% to $19.6 million in 2023, then skyrocketed by 30.54% to $25.6 million in 2024, then increased by 23.32% to $31.6 million in 2025.
  • Its Cash & Equivalents stands at $31.6 million for Q3 2025, versus $36.0 million for Q2 2025 and $46.6 million for Q1 2025.